Sa1899 CLINICAL IMPLICATIONS OF INFLIXIMAB AND ADALIMUMAB THERAPEUTIC DRUG MONITORING BEFORE AND AFTER THE IMPLEMENTATION OF CORRECTIVE MEASURES FOR THE HOMOGENEOUS MOBILITY SHIFT ASSAY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE